🇺🇸 Guanfacine extended-release tablets in United States

11 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dizziness — 2 reports (18.18%)
  2. Fatigue — 1 report (9.09%)
  3. Headache — 1 report (9.09%)
  4. Lethargy — 1 report (9.09%)
  5. Nightmare — 1 report (9.09%)
  6. Product Contamination — 1 report (9.09%)
  7. Recalled Product Administered — 1 report (9.09%)
  8. Sleep Disorder — 1 report (9.09%)
  9. Somnolence — 1 report (9.09%)
  10. Therapy Non-Responder — 1 report (9.09%)

Source database →

Guanfacine extended-release tablets in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Guanfacine extended-release tablets approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Guanfacine extended-release tablets in United States?

Children's Specialized Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.